Long-­‐term Outcome of Combined (Perilesional InjecGon and Topical) Interferon Alpha-­‐2b Therapy in the Management of Ocular Surface Squamous Neoplasia


Creative Commons License

Özer M. D. , Tuncer S.

International Society of Ocular Oncology Congress, Paris, France, 16 - 19 June 2015, pp.180

  • Publication Type: Conference Paper / Summary Text
  • City: Paris
  • Country: France
  • Page Numbers: pp.180

Abstract

Purpose: To report the efficacy of combined (perilesional injection and topical) interferon alpha-­‐2b (IFNα2b) therapy in the management of lesions clinically diagnosed as ocular surface squamous neoplasia (OSSN).

Materials and Methods: Thirty-­‐seven eyes of 37 patients that were treated with recombinant IFNα2b between January 2004 and February 2015 were evaluated non-comparatively and retrospectively. Perilesional injection of IFNα2b along with topical IFNα2b drops was applied to all subjects. Adjuvant topical IFNα2b drops were continued for 2 months, after the complete resolution of the lesion with perilesional injections.

Results: The mean age of patients at presentation was 65 years (range, 30-­95 years). Clinical subtypes of OSSN were leukoplakic in 46% (n=17), papillomatous in 30% (n=11), mixed-­type in 8% (n=3), and diffuse in 16% (n=6) of the cases. The mean number of perilesional injections the OSSN was 5 (3-­21 range) for complete resolution. The mean duration of treatment until complete resolution of the tumor was 15 weeks (8-­40 weeks). After a mean follow-­up period of 58 months (5-­126 months), perilesional injection plus topical treatment with IFNα2b achieved complete tumor control in 100% of the cases. Tumor recurrence was not noted in any case during follow-­‐up. Ocular side effects included conjunctival hyperemia (n = 13, 35%), ocular irritation (n = 15, 40%), superficial punctate keraGGs (n = 18, 49%), and conjunctival follicles (n = 2, <1%). Systemic side effects included posGnjecGon flu-­‐like syndrome for 1 day (n = 20, 54%).

Conclusion: Combined (perilesional injection and topical) therapy with IFNα2b has provided long-­‐term complete tumor control in 100% of the cases without any recurrence.